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Brief CommunicationsWe strongly believe that this technique may occasionally be an
attractive approach when pedicled ITA is not long enough to be
used for sequential bypass grafting.
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coronary artery. Texas Heart Inst J. 2000;27:70-1.Activated recombinant factor VII for refractory bleeding during
extracorporeal membrane oxygenation
Ann Verrijckt, MD,a Franc¸ois Proulx, MD,a Sylvain Morneau, RRT,a and Suzanne Vobecky, MD,b Montreal, Quebec,
CanadaHemorrhagic complications are a major concern forpatients undergoing extracorporeal membrane oxy-genation (ECMO) after cardiac surgery. Transfusionsof platelets, fresh-frozen plasma and cryoprecipitates
are commonly used to improve hemostasis, sometimes in associ-
ation with antifibrinolytic agents or protease inhibitors.
Activated recombinant factor VII (rFVIIa; Novoseven, Novo
Nordisk, Denmark) was originally envisioned for the treatment of
bleeding in patients with hemophilia in whom inhibiting antibodies
to factor VIII developed. Most recently, rFVIIa has also been
successfully used among critically ill patients with impaired
thrombin generation and severe hemorrhage after major trauma,
liver failure or transplantation, and overdose of oral anticoagu-
lants. We report the case of a child undergoing ECMO with
refractory thoracic bleeding, which was controlled by a single dose
of rFVIIa (30 g/kg).
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A term, 3.2-kg male neonate had dextro-transposition of the great
arteries diagnosed on the first day after birth. Prostaglandin E1
infusion was started, and a Rashkind atrial septostomy was per-
formed on the second day after birth. The arterial switch operation
was postponed until the 12th day of life because of intracerebral
hemorrhages with subdural, subarachnoidal, and intraventricular
components (diameter 8 mm).
The platelet count and coagulogram were within normal limits.
Results of screening studies for congenital coagulation factor
deficiencies were also normal. Although the child remained free of
symptoms and repeated cerebral computed tomography showed a
decreased size of the hematoma, he received seizure prophylaxis
with phenobarbital. After uneventful anesthetic induction, an ar-
terial switch operation was performed, with ligation of the arterial
duct and closure of the atrial septostomy under cardiopulmonary
bypass (221 minutes) with moderate hypothermia (29°C) and
aortic crossclamping (83 minutes). Aprotinin was administered
during surgery, followed by protamine during weaning. Abnormal
circumflex coronary artery originating from the right coronary
artery was felt to be responsible for persistent left ventricular
failure, leading to unsuccessful weaning from cardiopulmonary
bypass and the requirement for venoarterial ECMO support with a
Carmeda coated circuit (Medtronic, Minneapolis, Minn). During
the first 2 days, the postoperative phase was characterized by
severe bleeding from the chest tubes (10 mL/kg/h), despite mas-
sive transfusion of blood products (7.7 mL/kg/h packed red blood
cells, 4.1 mL/kg/h platelets, and 2.6 mL/kg/h fresh-frozen plasma)
and calcium chloride.
Surgical reexplorations at 24 and 36 hours after the operation
failed to reveal any active surgical bleeding site. Because of
persistent hemorrhage from the thoracic chest tubes, aminocaproic
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Brief Communicationsacid (100 mg/kg) was given intravenously, without any effect.
Subsequently, rFVIIa (30 g/kg) was administered intravenously.
The hematologic parameters before and after rFVIIa administra-
tion are shown in Table 1. On the following days, the patient’s
condition remained stable with a significant reduction in the
amount of blood loss and without any apparent thrombotic event.
On the fifth postoperative day, the child was weaned from ECMO.
Despite maximal supportive therapy, he died of persistent left
ventricular failure on the 11th postoperative day. Autopsy was
refused by the parents.
Discussion
In this study, we noted that a single 30-g/kg dose of rFVIIa
decreased persistent thoracic bleeding associated to cardiac
ECMO. Similar findings have been reported by Tobias and col-
leagues,1 who used 70 g/kg rFVIIa in a 4-month-old child who
had postoperative hemorrhage after repair of an atrial septal defect.
Recently, Leibovitch and associates2 reported the successful un-
complicated use of 4 doses of rFVIIa (100 g/kg in each dose) in
the treatment of pulmonary hemorrhage after cardiac surgery in a
10-week-old infant.
During ECMO, nonsurgical bleeding may result from heparin
overdose or consumptive coagulopathy related to hemodilution,
thrombocytopenia, decreased platelet function, deficiency of co-
agulation factors, and hyperfibrinolysis. In additional to conven-
tional therapy with transfusion of blood components, antifibrino-
lytic agents may decrease the bleeding tendency at the site of tissue
damage without significant risk of vascular thrombosis. When
these conventional therapies fail, as in our case, rFVIIa becomes a
potentially interesting alternative. This drug may bind tissue factor
at sites of vascular damage, thereby leading to thrombin formation,
a process involving factors IX and X. Alternatively rFVIIa may
activate factor X on activated platelets independently of the pres-
ence of tissue factor.3-4
In addition, rFVIIa may play a significant role as a more
general hemostatic agent beyond its indications in the treatment of
hemophilia complicated by inhibiting antibodies. Experience with
its use in cardiac surgery remains limited, mainly out of fear of
thrombotic complications in patients with underlying atheroscle-
rotic disease and areas of tissue factor expression in addition to
their bleeding source on atherosclerotic plaques. The successful
perioperative or postoperative use of rFVIIa has been reported in
a limited number of adult cardiac surgery patients without any
apparent thrombotic event. However, Bui and colleagues5 reported
that the use of rFVIIa (90 g/kg) followed by administration of
activated prothrombin complex in a patient undergoing ECMO
resulted in massive thrombosis of the circuit and death.The Journal of ThoracicIn conclusion, we report here the first case of a child undergo-
ing ECMO with refractory thoracic bleeding that was controlled
with a single dose of rFVIIa. We emphasize that the risk-benefit
ratio and the cost-effectiveness of rFVIIa in this population remain
unclear. Further characterization of the mechanisms of action of
rFVIIa may lead to well-designed, controlled studies.
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TABLE 1. Hematologic parameters before and after recom-
binant activated factor VII (rFVIIa) during venoarterial ex-
tracorporeal membrane oxygenation
Before After
Chest tube bleeding* (mL/[kg · h]) 9.1 3.5
Platelet count (cells/mm3) 89000 125,000
Prothrombin time (s)† 15.3 10
International normalized ratio† 1.24 0.72
Activated partial thromboplastin time† (s) 135 114
Activated clotting time‡ (s) 164 148
*Represents the mean chest tube drainage during 4 hours before (41, 26,
28, 22 mL) and after (22, 4, 15, 5 mL) the use of rFVIIa (30 g/kg). Because
rFVIIa was administered half an hour after the last measurement of
thoracic tube drainage, which was calculated on an hourly basis, data
during the first hour most likely underestimate the effect of the maneuver.
†Represents the prothrombin time, international normalized ratio, and
activated partial thromboplastin time before and 30 minutes after rFVIIa.
The prothrombin time increased to 12.1 (international normalized ratio 0.92)
4 hours later.
‡Heparin was administered before (45 U/kg/h) and after (72 U/kg/h) rFVIIa.and Cardiovascular Surgery ● Volume 127, Number 6 1813
